Iris Tavor

General Counsel at ENLIVEX THERAPEUTICS LTD.

Health Technology

Commercial Services

Profile

Iris Tavor is currently a Senior Director of Regulatory and Quality Affairs at Enlivex Therapeutics Ltd.
She previously worked as the Head of Quality and Regulatory Affairs at Pluristem Ltd.

Iris Tavor active positions

Companies	Position	Start
ENLIVEX THERAPEUTICS LTD.	General Counsel	-

All active positions of Iris Tavor

Former positions of Iris Tavor

Companies	Position	End
Pluristem Ltd. Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003.	General Counsel	-

See the detail of Iris Tavor's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Iris Tavor's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ENLIVEX THERAPEUTICS LTD.	Health Technology

Private companies	1
Pluristem Ltd. Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003.	Commercial Services